Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer

Author(s): Yi-Long Wu, M.D.1; Maximilian Hochmair, M.D.2; Yi Yang, M.D.3; Xue-Ning Yang, M.D.1; Masahiro Tsuboi, M.D.4; Luis Paz-Ares, M.D., Ph.D.5; James Chih-Hsin Yang, M.D., Ph.D.6; Lin Wu, M.D.7; Hye Ryun Kim, M.D., Ph.D.8; Damian T. Rieke, M.D.9; Melissa Johnson, M.D.10; Benjamin Besse, M.D., Ph.D.11; Nivedita Sharma, M.D.12; Patricia Maeda, M.D.12; Patrick Peterson, Ph.D.12; Boris Kin Lin, M.D., Ph.D.12; Bente Frimodt-Moller, M.Sc.13; Jonathan Goldman, M.D.14; Alexander Drilon, M.D.15; the LIBRETTO-432 Trial Investigators†;
Source: DOI: 10.1056/NEJMoa2602628

Dr. Maen Hussein's Thoughts

109 patients with stage II or IIIA disease, 2-year investigator-assessed event-free survival was 92% with selpercatinib and 61% with placebo (HR for disease recurrence, progression, or death, 0.17 P<0.001). Patients with stage IB, II, or IIIA non–small-cell lung cancer (NSCLC), event-free survival at 2 years was 94% with selpercatinib and 70% with placebo. Genomic testing is expanding now for early stage NSCLC. More study in the adjuvant setting showing promise with targeted therapy.

BACKGROUND

Selpercatinib, a highly selective, potent, and central nervous system–penetrant RET inhibitor, is approved for RET fusion–positive advanced or metastatic non–small-cell lung cancer (NSCLC). The efficacy and safety of selpercatinib in early-stage NSCLC are unknown.

METHODS

We conducted a phase 3, double-blind trial involving patients with RET fusion–positive NSCLC who had received definitive therapy with curative intent (surgery or radiotherapy with adjuvant systemic anticancer therapy, if applicable). Patients were randomly assigned to receive adjuvant selpercatinib or placebo for up to 3 years. The primary end point was investigator-assessed event-free survival in patients with stage II or IIIA disease. Secondary end points were investigator-assessed event-free survival in patients with stage IB, II, or IIIA disease; event-free survival as assessed by blinded independent central review; overall survival; and safety. Research Summary Selpercatinib in Early-Stage RET Fusion–Positive NSCLC

RESULTS

A total of 151 patients were assigned to receive selpercatinib (75 patients) or placebo (76 patients). Median follow-up was 24 months and 27 months in the respective groups. Among 109 patients with stage II or IIIA disease, 2-year investigator-assessed event-free survival was 92% with selpercatinib and 61% with placebo (hazard ratio for disease recurrence, progression, or death, 0.17; 95% confidence interval [CI], 0.06 to 0.51; P

CONCLUSIONS

Among patients with stage II or IIIA RET fusion–positive NSCLC, event-free survival was significantly longer with adjuvant selpercatinib than with placebo. (Funded by Lilly; LIBRETTO-432 ClinicalTrials.gov number, NCT04819100.) Quick Take Adjuvant Selpercatinib in RET Fusion–Positive NSCLC 2m 33s

Author Affiliations

1Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China; 2Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna; 3Department of Thoracic Surgery, Affiliated Hospital of Southwest Jiaotong University, College of Medicine, Southwest Jiaotong University, Third People’s Hospital of Chengdu, Chengdu, China; 4National Cancer Center Hospital East, Kashiwa, Japan; 5Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid; 6National Taiwan University Hospital, NTU Cancer Center, Taipei; 7Hunan Cancer Hospital, Changsha, China; 8Division of Medical Oncology, Department of Internal Medicine, Yonsei University Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; 9Charité–Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin; 10Sarah Cannon Research Institute, Nashville; 11Paris Saclay University, Gustave Roussy, Villejuif, France; 12Lilly, Indianapolis; 13Lilly, Copenhagen; 14University of California, Los Angeles, Los Angeles; 15Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

Daraxonrasib for Previously Treated RAS-Mutant Non–Small-Cell Lung Cancer

This feels like the first real crack in the "undruggable" non-G12C RAS wall in lung cancer: a pan-RAS(ON) inhibitor with responses across G12D, G12V, and other alleles in patients who had already received platinum and immunotherapy. At the 160–220 mg range (the phase 3 dose is 200 mg), patients who hadn't yet received docetaxel had a 42% response rate, median progression-free survival (PFS) of 8 mos, and median overall survival (OS) of 16 mos, which looks well ahead of what we expect from docetaxel, though that's a cross-trial comparison. The catch is tolerability: about half had grade 3 or higher events, 9 in 10 got rash, and most got diarrhea, so rash prophylaxis and proactive GI management will matter just as it does on PDAC. The randomized RASolve 301 trial against docetaxel is the one to watch before this moves into practice.

Read More »

SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1–High, Locally Advanced, Unresectable or Metastatic Non–Small Cell Lung Cancer

This is another nail in the anti-TIGIT coffin. In more than 500 patients with untreated PD-L1–high non–small cell lung cancer (NSCLC), adding tiragolumab to atezolizumab missed both primary endpoints, and the numerical progression-free survival (PFS) and overall survival (OS) gains never reached significance. What it did add was toxicity: twice the grade 3–4 adverse events (AEs) and more discontinuations. Together with the other failed TIGIT programs, this pretty much closes the door on chemo-free anti-TIGIT combinations in first-line NSCLC, so single-agent PD-(L)1 or chemo-IO stays the standard for these patients.

Read More »

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations

Progression-free survival (PFS) was higher in the Sun group vs chemotherapy, 10.3 m vs 7.5 m with HR of .65 with higher responses (58.9% vs 31.1%) diarrhea high CK and anemia were the most common side effects. The issue is that amivan was not part of treatment and compared to chemotherapy ami in addition to chemotherapy had 11m PFS also in this trial few had brain mets so no evaluation for CNS protection or treatment. But an oral agent in patients who don’t want to come to the office often.

Read More »

Ensartinib in Resected ALK-Positive Non–Small-Cell Lung Cancer

It seems the old cliche of more drugs than patients is becoming true for most providers here. The data needs to mature further here but likely this will be another option for Anaplastic lymphoma kinase (ALK)+ non–small-cell lung cancer (NSCLC) patients in the adjuvant setting. It does look like CNS protection benefits are meaningful as well.

Read More »